Point-of-care biosensor system

10.2741/s357 ◽  
2013 ◽  
Vol S5 (1) ◽  
pp. 39-71 ◽  
Author(s):  
Arvind Sai Sarathi Vasan
Keyword(s):  
Point Of Care ◽  
Biosensor System

scholarly journals A Novel Microfluidic Point-of-Care Biosensor System on Printed Circuit Board for Cytokine Detection

Sensors ◽  
2018 ◽  
Vol 18 (11) ◽  
pp. 4011 ◽  
Author(s):  
Daniel Evans ◽  
Konstantinos Papadimitriou ◽  
Nikolaos Vasilakis ◽  
Panagiotis Pantelidis ◽  
Peter Kelleher ◽  
...  
Keyword(s):  
Printed Circuit Board ◽  
Point Of Care ◽  
Reference Electrode ◽  
Circuit Board ◽  
Enzyme Linked Immunosorbent Assay ◽  
Interferon Gamma Release Assay ◽  
Counter Electrodes ◽  
Printed Circuit ◽  
Cytokine Detection ◽  
Biosensor System

Point of Care (PoC) diagnostics have been the subject of considerable research over the last few decades driven by the pressure to detect diseases quickly and effectively and reduce healthcare costs. Herein, we demonstrate a novel, fully integrated, microfluidic amperometric enzyme-linked immunosorbent assay (ELISA) prototype using a commercial interferon gamma release assay (IGRA) as a model antibody binding system. Microfluidic assay chemistry was engineered to take place on Au-plated electrodes within an assay cell on a printed circuit board (PCB)-based biosensor system. The assay cell is linked to an electrochemical reporter cell comprising microfluidic architecture, Au working and counter electrodes and a Ag/AgCl reference electrode, all manufactured exclusively via standard commercial PCB fabrication processes. Assay chemistry has been optimised for microfluidic diffusion kinetics to function under continual flow. We characterised the electrode integrity of the developed platforms with reference to biological sampling and buffer composition and subsequently we demonstrated concentration-dependent measurements of H2O2 depletion as resolved by existing FDA-validated ELISA kits. Finally, we validated the assay technology in both buffer and serum and demonstrate limits of detection comparable to high-end commercial systems with the addition of full microfluidic assay architecture capable of returning diagnostic analyses in approximately eight minutes.

Automatic smartphone-based microfluidic biosensor system at the point of care

2018 ◽  
Vol 110 ◽  
pp. 78-88 ◽  
Author(s):  
Dandan Xu ◽  
Xiwei Huang ◽  
Jinhong Guo ◽  
Xing Ma
Keyword(s):  
Point Of Care ◽  
Biosensor System ◽  
Microfluidic Biosensor

scholarly journals Monitoring Thrombin Generation by Electrochemistry: Development of an Amperometric Biosensor Screening Test for Plasma and Whole Blood

2009 ◽  
Vol 55 (3) ◽  
pp. 505-512 ◽  
Author(s):  
Charles Thuerlemann ◽  
André Haeberli ◽  
Lorenzo Alberio
Keyword(s):  
Whole Blood ◽  
Thrombin Generation ◽  
Platelet Rich Plasma ◽  
Point Of Care ◽  
Electrical Signal ◽  
Measuring System ◽  
Screening Tests ◽  
Blood Samples ◽  
Biosensor System ◽  
Whole Blood Samples

Abstract Background: Complete investigation of thrombophilic or hemorrhagic clinical presentations is a time-, apparatus-, and cost-intensive process. Sensitive screening tests for characterizing the overall function of the hemostatic system, or defined parts of it, would be very useful. For this purpose, we are developing an electrochemical biosensor system that allows measurement of thrombin generation in whole blood as well as in plasma. Methods: The measuring system consists of a single-use electrochemical sensor in the shape of a strip and a measuring unit connected to a personal computer, recording the electrical signal. Blood is added to a specific reagent mixture immobilized in dry form on the strip, including a coagulation activator (e.g., tissue factor or silica) and an electrogenic substrate specific to thrombin. Results: Increasing thrombin concentrations gave standard curves with progressively increasing maximal current and decreasing time to reach the peak. Because the measurement was unaffected by color or turbidity, any type of blood sample could be analyzed: platelet-poor plasma, platelet-rich plasma, and whole blood. The test strips with the predried reagents were stable when stored for several months before testing. Analysis of the combined results obtained with different activators allowed discrimination between defects of the extrinsic, intrinsic, and common coagulation pathways. Activated protein C (APC) predried on the strips allowed identification of APC-resistance in plasma and whole blood samples. Conclusions: The biosensor system provides a new method for assessing thrombin generation in plasma or whole blood samples as small as 10 μL. The assay is easy to use, thus allowing it to be performed in a point-of-care setting.

An inkjet-printed smartphone-supported electrochemical biosensor system for reagentless point-of-care analyte detection

2021 ◽  
pp. 130447
Author(s):  
Yang Bai ◽  
Qiuquan Guo ◽  
Junfeng Xiao ◽  
Mingyue Zheng ◽  
Dongxing Zhang ◽  
...  
Keyword(s):  
Electrochemical Biosensor ◽  
Point Of Care ◽  
Biosensor System ◽  
Analyte Detection

scholarly journals Smartphone Biosensor System with Multi-Testing Unit Based on Localized Surface Plasmon Resonance Integrated with Microfluidics Chip

Sensors ◽  
2020 ◽  
Vol 20 (2) ◽  
pp. 446 ◽  
Author(s):  
Zhiyuan Fan ◽  
Zhaoxin Geng ◽  
Weihao Fang ◽  
Xiaoqing Lv ◽  
Yue Su ◽  
...  
Keyword(s):  
Surface Plasmon Resonance ◽  
Surface Plasmon ◽  
Plasmon Resonance ◽  
Localized Surface Plasmon Resonance ◽  
Point Of Care ◽  
Localized Surface Plasmon ◽  
Point Of Care Testing ◽  
Testing Unit ◽  
Biosensor System ◽  
Multiple Biomarkers

Detecting biomarkers is an efficient method to diagnose and monitor patients’ stages. For more accurate diagnoses, continuously detecting and monitoring multiple biomarkers are needed. To achieve point-of-care testing (POCT) of multiple biomarkers, a smartphone biosensor system with the multi-testing-unit (SBSM) based on localized surface plasmon resonance (LSPR) integrated multi-channel microfluidics was presented. The SBSM could simultaneously record nine sensor units to achieve the detection of multiple biomarkers. Additional 72 sensor units were fabricated for further verification. Well-designed modularized attachments consist of a light source, lenses, a grating, a case, and a smartphone shell. The attachments can be well assembled and attached to a smartphone. The sensitivity of the SBSM was 161.0 nm/RIU, and the limit of detection (LoD) reached 4.2 U/mL for CA125 and 0.87 U/mL for CA15-3 through several clinical serum specimens testing on the SBSM. The testing results indicated that the SBSM was a useful tool for detecting multi-biomarkers. Comparing with the enzyme-linked immunosorbent assays (ELISA) results, the results from the SBSM were correlated and reliable. Meanwhile, the SBSM was convenient to operate without much professional skill. Therefore, the SBSM could become useful equipment for point-of-care testing due to its small size, multi-testing unit, usability, and customizable design.

scholarly journals Programmable Bio-nanochip Platform: A Point-of-Care Biosensor System with the Capacity To Learn

2016 ◽  
Vol 49 (7) ◽  
pp. 1359-1368 ◽  
Author(s):  
Michael P. McRae ◽  
Glennon Simmons ◽  
Jorge Wong ◽  
John T. McDevitt
Keyword(s):  
Point Of Care ◽  
Biosensor System

“Aspirin - resistance”? A few critical considerations on definition, terminology, diagnosis, clinical value, natural course of atherosclerotic disease, and therapeutic consequences

VASA ◽  
2011 ◽  
Vol 40 (6) ◽  
pp. 429-438 ◽  
Author(s):  
Berent ◽  
Sinzinger
Keyword(s):  
Platelet Function ◽  
Point Of Care ◽  
Aspirin Resistance ◽  
Point Of View ◽  
Evidence Based ◽  
Platelet Function Tests ◽  
Clinical Value ◽  
Vascular Events ◽  
Therapeutic Consequences ◽  
Function Tests

Based upon various platelet function tests and the fact that patients experience vascular events despite taking acetylsalicylic acid (ASA or aspirin), it has been suggested that patients may become resistant to the action of this pharmacological compound. However, the term “aspirin resistance” was created almost two decades ago but is still not defined. Platelet function tests are not standardized, providing conflicting information and cut-off values are arbitrarily set. Intertest comparison reveals low agreement. Even point of care tests have been introduced before appropriate validation. Inflammation may activate platelets, co-medication(s) may interfere significantly with aspirin action on platelets. Platelet function and Cox-inhibition are only some of the effects of aspirin on haemostatic regulation. One single test is not reliable to identify an altered response. Therefore, it may be more appropriate to speak about “treatment failure” to aspirin therapy than using the term “aspirin resistance”. There is no evidence based justification from either the laboratory or the clinical point of view for platelet function testing in patients taking aspirin as well as from an economic standpoint. Until evidence based data from controlled studies will be available the term “aspirin resistance” should not be further used. A more robust monitoring of factors resulting in cardiovascular events such as inflammation is recommended.

Sign in / Sign up

Export Citation Format

Share Document